BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer 2019;19:698-715. [PMID: 31666715 DOI: 10.1038/s41568-019-0210-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 102] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen R, Wang X, Fu J, Liang M, Xia T. High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer. Front Genet 2022;13:956869. [DOI: 10.3389/fgene.2022.956869] [Reference Citation Analysis]
2 Matola AT, Józsi M, Uzonyi B. Overview on the role of complement-specific autoantibodies in diseases. Mol Immunol 2022;151:52-60. [PMID: 36084516 DOI: 10.1016/j.molimm.2022.08.011] [Reference Citation Analysis]
3 Yang H, Che D, Gu Y, Cao D. Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma. Front Genet 2022;13:940306. [DOI: 10.3389/fgene.2022.940306] [Reference Citation Analysis]
4 Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 2022. [PMID: 35974096 DOI: 10.1038/s41573-022-00520-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu X, Wang Y, Bauer AT, Kirschfink M, Ding P, Gebhardt C, Borsig L, Tüting T, Renné T, Häffner K, Hu W, Schneider SW, Gorzelanny C. Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels. Proc Natl Acad Sci U S A 2022;119:e2122716119. [PMID: 35960843 DOI: 10.1073/pnas.2122716119] [Reference Citation Analysis]
6 Chikhaoui A, Jones M, Režen T, Ben Ahmed M, Naouali C, Komel R, Zghal M, Boubaker S, Abdelhak S, Yacoub-Youssef H. Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma. Sci Rep 2022;12:13854. [PMID: 35974070 DOI: 10.1038/s41598-022-17928-z] [Reference Citation Analysis]
7 Magrini E, Minute L, Dambra M, Garlanda C. Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression. Semin Immunol 2022;:101642. [PMID: 35842274 DOI: 10.1016/j.smim.2022.101642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dobó J, Kocsis A, Dani R, Gál P. Proprotein Convertases and the Complement System. Front Immunol 2022;13:958121. [DOI: 10.3389/fimmu.2022.958121] [Reference Citation Analysis]
9 Kolev M, Das M, Gerber M, Baver S, Deschatelets P, Markiewski MM. Inside-Out of Complement in Cancer. Front Immunol 2022;13:931273. [DOI: 10.3389/fimmu.2022.931273] [Reference Citation Analysis]
10 Diego-gonzález L, Fernández-carrera A, Igea A, Martínez-pérez A, Real Oliveira MECD, Gomes AC, Guerra C, Barbacid M, González-fernández Á, Simón-vázquez R. Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. Cancers 2022;14:3102. [DOI: 10.3390/cancers14133102] [Reference Citation Analysis]
11 Zhang Q, Zhang W, Lin T, Lu W, He X, Ding Y, Chen W, Diao W, Ding M, Shen P, Guo H. Mass cytometry reveals immune atlas of urothelial carcinoma. BMC Cancer 2022;22:677. [PMID: 35725444 DOI: 10.1186/s12885-022-09788-7] [Reference Citation Analysis]
12 Deyhle MR, Callaway CS, Neyroud D, D'Lugos AC, Judge SM, Judge AR. Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy. Cells 2022;11:1893. [PMID: 35741022 DOI: 10.3390/cells11121893] [Reference Citation Analysis]
13 Bahri R, Kiss O, Prise I, Garcia-rodriguez KM, Atmoko H, Martínez-gómez JM, Levesque MP, Dummer R, Smith MP, Wellbrock C, Bulfone-paus S. Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. Front Immunol 2022;13:861545. [DOI: 10.3389/fimmu.2022.861545] [Reference Citation Analysis]
14 Lu C, Miao J, Li M, Zheng Q, Xu F, Pan Y, Wang Y, Yang Z, Xia X, Zhu H, Chen J, Bao S. Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Front Oncol 2022;12:870840. [DOI: 10.3389/fonc.2022.870840] [Reference Citation Analysis]
15 Abril-Parreño L, Meade KG, Krogenæs AK, Druart X, Cormican P, Fair S. Ewe breed differences in the cervical transcriptome at the follicular phase of a synchronised oestrous cycle. BMC Genomics 2022;23:363. [PMID: 35546662 DOI: 10.1186/s12864-022-08603-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hamilton PT, Anholt BR, Nelson BH. Tumour immunotherapy: lessons from predator-prey theory. Nat Rev Immunol 2022. [PMID: 35513493 DOI: 10.1038/s41577-022-00719-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kolka CM, Webster J, Lepletier A, Winterford C, Brown I, Richards RS, Zelek WM, Cao Y, Khamis R, Shanmugasundaram KB, Wuethrich A, Trau M, Brosda S, Barbour A, Shah AK, Eslick GD, Clemons NJ, Morgan BP, Hill MM. C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. Front Immunol 2022;13:842023. [PMID: 35345676 DOI: 10.3389/fimmu.2022.842023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Janneh AH, Ogretmen B. Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment. Cancers (Basel) 2022;14:2183. [PMID: 35565311 DOI: 10.3390/cancers14092183] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Qu Y, Feng J, Wu X, Bai L, Xu W, Zhu L, Liu Y, Xu F, Zhang X, Yang G, Lv J, Chen X, Shi GH, Wang HK, Cao DL, Xiang H, Li L, Tan S, Gan HL, Sun MH, Qiu J, Zhang H, Zhao JY, Ye D, Ding C. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nat Commun 2022;13:2052. [PMID: 35440542 DOI: 10.1038/s41467-022-29577-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zhang L, Lin W, Zhou Y, Shao F, Gao Y, He J. A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients. Front Cell Dev Biol 2022;10:765062. [DOI: 10.3389/fcell.2022.765062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ye M, Chen Y, Liu J, Tian J, Wang X, Fok KL, Shi J, Chen H. Interfering with CSE1L/CAS inhibits tumour growth via C3 in triple-negative breast cancer. Cell Prolif 2022;:e13226. [PMID: 35403306 DOI: 10.1111/cpr.13226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 2022. [PMID: 35393541 DOI: 10.1038/s41568-022-00466-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
23 Singh AK, Malviya R. Coagulation and inflammation in cancer: Limitations and prospects for treatment. Biochim Biophys Acta Rev Cancer 2022;:188727. [PMID: 35378243 DOI: 10.1016/j.bbcan.2022.188727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol 2022. [PMID: 35365796 DOI: 10.1038/s41571-022-00619-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
25 Wang X, Zhang W. The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. J Control Release 2022:S0168-3659(22)00189-4. [PMID: 35367478 DOI: 10.1016/j.jconrel.2022.03.056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Cedzyński M, Świerzko AS. Components of the Lectin Pathway of Complement in Solid Tumour Cancers. Cancers 2022;14:1543. [DOI: 10.3390/cancers14061543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Qi R, Qin W. Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application. Front Immunol 2022;13:811696. [PMID: 35281019 DOI: 10.3389/fimmu.2022.811696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Revel M, Sautès-fridman C, Fridman W, Roumenina LT. C1q+ macrophages: passengers or drivers of cancer progression. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Johnson EM, Uppalapati CK, Pascual AS, Estrada SI, Averitte RL, Leyva KJ, Hull EE. Complement Factor H in cSCC: Evidence of a Link Between Sun Exposure and Immunosuppression in Skin Cancer Progression. Front Oncol 2022;12:819580. [PMID: 35223500 DOI: 10.3389/fonc.2022.819580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 2022:S1074-7613(22)00081-4. [PMID: 35231421 DOI: 10.1016/j.immuni.2022.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
31 Luo L, Deng S, Tang W, Hu X, Yin F, Ge H, Tang J, Liao Z, Li X, Feng J. Recruitment of IL-1β-producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion. Thorac Cancer 2022. [PMID: 35137541 DOI: 10.1111/1759-7714.14324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Srinivasan S, Kryza T, Batra J, Clements J. Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer 2022. [PMID: 35102281 DOI: 10.1038/s41568-021-00436-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Liu X, Zhu M, Wang X, Dong X, Liu H, Li R, Jia S, Lu Q, Zhao M, Sun P, Chen H, Fang C. A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01265-4] [Reference Citation Analysis]
34 Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020. Cancer Immunol Immunother 2022. [PMID: 35034143 DOI: 10.1007/s00262-022-03145-0] [Reference Citation Analysis]
35 Galmiche A, Rak J, Roumenina LT, Saidak Z. Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer 2022:S2405-8033(21)00261-2. [PMID: 35027336 DOI: 10.1016/j.trecan.2021.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
36 Rahmati Nezhad P, Riihilä P, Knuutila JS, Viiklepp K, Peltonen S, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2022;14:305. [PMID: 35053469 DOI: 10.3390/cancers14020305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Cilibrasi C, Simon T, Vintu M, Tolias C, Samuels M, Mazarakis NK, Eravci M, Stewart N, Critchley G, Giamas G. Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients. Biomedicines 2022;10:125. [DOI: 10.3390/biomedicines10010125] [Reference Citation Analysis]
38 Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treatment Reviews 2022;102:102322. [DOI: 10.1016/j.ctrv.2021.102322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Al Saber M, Biswas P, Dey D, Kaium MA, Islam MA, Tripty MIA, Rahman MH, Rahaman TI, Biswas MY, Paul P, Rahman MA, Hasan MN, Kim B. A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. Processes 2022;10:16. [DOI: 10.3390/pr10010016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Welte T, Mai J, Zhang Z, Tian S, Zhang G, Xu Y, Zhang L, Chen SS, Wang T, Shen H. A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. iScience 2021;24:103349. [PMID: 34825135 DOI: 10.1016/j.isci.2021.103349] [Reference Citation Analysis]
41 Moon EJ, Petersson K, Olcina MM. The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. Int J Radiat Biol 2021;:1-13. [PMID: 34726575 DOI: 10.1080/09553002.2021.1988178] [Reference Citation Analysis]
42 van de Bovenkamp FS, Dijkstra DJ, van Kooten C, Gelderman KA, Trouw LA. Circulating C1q levels in health and disease, more than just a biomarker. Mol Immunol 2021;140:206-16. [PMID: 34735869 DOI: 10.1016/j.molimm.2021.10.010] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Viiklepp K, Nissinen L, Ojalill M, Riihilä P, Kallajoki M, Meri S, Heino J, Kähäri VM. C1r Upregulates Production of Matrix Metalloproteinase-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma. J Invest Dermatol 2021:S0022-202X(21)02379-4. [PMID: 34756877 DOI: 10.1016/j.jid.2021.10.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
44 Netti GS, Franzin R, Stasi A, Spadaccino F, Dello Strologo A, Infante B, Gesualdo L, Castellano G, Ranieri E, Stallone G. Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers. Cells 2021;10:2426. [PMID: 34572075 DOI: 10.3390/cells10092426] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Magrini E, Di Marco S, Mapelli SN, Perucchini C, Pasqualini F, Donato A, de la Luz Guevara Lopez M, Carriero R, Ponzetta A, Colombo P, Cananzi F, Supino D, Reis ES, Peano C, Inforzato A, Jaillon S, Doni A, Lambris JD, Mantovani A, Garlanda C. Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nat Cancer 2021;2:218-32. [PMID: 34505065 DOI: 10.1038/s43018-021-00173-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
46 Chamseddine AN, Assi T, Mir O, Chouaib S. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Pharmacol Ther 2021;:107986. [PMID: 34481812 DOI: 10.1016/j.pharmthera.2021.107986] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
47 Fridman WH, Petitprez F, Meylan M, Chen TW, Sun CM, Roumenina LT, Sautès-Fridman C. B cells and cancer: To B or not to B? J Exp Med 2021;218:e20200851. [PMID: 33601413 DOI: 10.1084/jem.20200851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
48 Lawal B, Tseng SH, Olugbodi JO, Iamsaard S, Ilesanmi OB, Mahmoud MH, Ahmed SH, Batiha GE, Wu ATH. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. Cancers (Basel) 2021;13:4124. [PMID: 34439277 DOI: 10.3390/cancers13164124] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Senent Y, Ajona D, González-Martín A, Pio R, Tavira B. The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers (Basel) 2021;13:3806. [PMID: 34359708 DOI: 10.3390/cancers13153806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Proctor M, Gonzalez Cruz JL, Daignault-Mill SM, Veitch M, Zeng B, Ehmann A, Sabdia M, Snell C, Keane C, Dolcetti R, Haass NK, Wells JW, Gabrielli B. Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers (Basel) 2021;13:3733. [PMID: 34359633 DOI: 10.3390/cancers13153733] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Goudsmit C, da Veiga Leprevost F, Basrur V, Peters L, Nesvizhskii A, Walline H. Differences in Extracellular Vesicle Protein Cargo Are Dependent on Head and Neck Squamous Cell Carcinoma Cell of Origin and Human Papillomavirus Status. Cancers (Basel) 2021;13:3714. [PMID: 34359613 DOI: 10.3390/cancers13153714] [Reference Citation Analysis]
52 Zhang N, Liu Y, Yang H, Liang M, Wang X, Wang M, Kong J, Yuan X, Zhou F. Clinical Significance of Fusobacterium nucleatum Infection and Regulatory T Cell Enrichment in Esophageal Squamous Cell Carcinoma. Pathol Oncol Res 2021;27:1609846. [PMID: 34305476 DOI: 10.3389/pore.2021.1609846] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
53 Guo H, Yan Z, Hu Y, Huang X, Pan C. Complement C7 is Specifically Expressed in Mesangial Cells and is a Potential Diagnostic Biomarker for Diabetic Nephropathy and is Regulated by miR-494-3p and miR-574-5p. Diabetes Metab Syndr Obes 2021;14:3077-88. [PMID: 34262312 DOI: 10.2147/DMSO.S311725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
54 Wei Y, Huang CX, Xiao X, Chen DP, Shan H, He H, Kuang DM. B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene 2021;40:4737-45. [PMID: 34188249 DOI: 10.1038/s41388-021-01918-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kołat D, Kałuzińska Ż, Bednarek AK, Płuciennik E. WWOX Loses the Ability to Regulate Oncogenic AP-2γ and Synergizes with Tumor Suppressor AP-2α in High-Grade Bladder Cancer. Cancers (Basel) 2021;13:2957. [PMID: 34204827 DOI: 10.3390/cancers13122957] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
56 Zhang YG, Niu JT, Wu HW, Si XL, Zhang SJ, Li DH, Bian TT, Li YF, Yan XK. Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy. Anal Cell Pathol (Amst) 2021;2021:6692811. [PMID: 34194957 DOI: 10.1155/2021/6692811] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
57 Khan A, Das BC, Abiha U, Sisodiya S, Chikara A, Nazir SU, Das AM, Rodrigues AG, Passari AK, Tanwar P, Hussain S, Rashid S, Rashid S. Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis. Semin Cancer Biol 2021:S1044-579X(21)00161-9. [PMID: 34087416 DOI: 10.1016/j.semcancer.2021.05.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr Opin Immunol 2021;72:126-34. [PMID: 34004375 DOI: 10.1016/j.coi.2021.04.005] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 Lu P, Ma Y, Wei S, Liang X. The dual role of complement in cancers, from destroying tumors to promoting tumor development. Cytokine 2021;143:155522. [PMID: 33849765 DOI: 10.1016/j.cyto.2021.155522] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
60 Schvarcz CA, Danics L, Krenács T, Viana P, Béres R, Vancsik T, Nagy Á, Gyenesei A, Kun J, Fonović M, Vidmar R, Benyó Z, Kaucsár T, Hamar P. Modulated Electro-Hyperthermia Induces a Prominent Local Stress Response and Growth Inhibition in Mouse Breast Cancer Isografts. Cancers (Basel) 2021;13:1744. [PMID: 33917524 DOI: 10.3390/cancers13071744] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Rahmati Nezhad P, Riihilä P, Piipponen M, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement factor I upregulates expression of matrix metalloproteinase-13 and -2 and promotes invasion of cutaneous squamous carcinoma cells. Exp Dermatol 2021. [PMID: 33813765 DOI: 10.1111/exd.14349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhu H, Yu X, Zhang S, Shu K. Targeting the Complement Pathway in Malignant Glioma Microenvironments. Front Cell Dev Biol 2021;9:657472. [PMID: 33869223 DOI: 10.3389/fcell.2021.657472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
63 Liu Y, Wang X. Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA. Clin Transl Oncol 2021;23:1923-33. [PMID: 33765255 DOI: 10.1007/s12094-021-02602-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Yeung OWH, Qi X, Pang L, Liu H, Ng KTP, Liu J, Lo CM, Man K. Type III TGF-β Receptor Down-Regulation Promoted Tumor Progression via Complement Component C5a Induction in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1503. [PMID: 33805946 DOI: 10.3390/cancers13071503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 O'Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N. Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers (Basel) 2021;13:1209. [PMID: 33802004 DOI: 10.3390/cancers13061209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Wang R, Wang Y, Hu L, Lu Z, Wang X. Inhibition of complement C5a receptor protects lung cells and tissues against lipopolysaccharide-induced injury via blocking pyroptosis. Aging (Albany NY) 2021;13:8588-98. [PMID: 33714207 DOI: 10.18632/aging.202671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Wen J, Wang L, Ren J, Kranz E, Chen S, Wu D, Kanazawa T, Chen I, Lu Y, Kamata M. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model. J Immunother Cancer 2021;9:e001524. [PMID: 33593826 DOI: 10.1136/jitc-2020-001524] [Reference Citation Analysis]
68 Cai X, Qiu W, Qian M, Feng S, Peng C, Zhang J, Wang Y, Wang Y. A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma. Front Cell Dev Biol 2020;8:615970. [PMID: 33614625 DOI: 10.3389/fcell.2020.615970] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 Pudova EA, Krasnov GS, Kobelyatskaya AA, Savvateeva MV, Fedorova MS, Pavlov VS, Nyushko KM, Kaprin AD, Alekseev BY, Trofimov DY, Sukhikh GT, Snezhkina AV, Kudryavtseva AV. Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced Stages. Front Genet 2020;11:613162. [PMID: 33552133 DOI: 10.3389/fgene.2020.613162] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
70 Mantovani A, Marchesi F, Jaillon S, Garlanda C, Allavena P. Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell Mol Immunol 2021;18:566-78. [PMID: 33473192 DOI: 10.1038/s41423-020-00613-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
71 Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol 2021;18:261-79. [PMID: 33469195 DOI: 10.1038/s41571-020-00459-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
72 Wang X, Ning W, Qiu Z, Li S, Zhang H, Yu C. Tumor-associated macrophages based signaling pathway analysis and hub genes identification in glioma. Medicine (Baltimore) 2020;99:e23840. [PMID: 33371165 DOI: 10.1097/MD.0000000000023840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Rodrigues PRS, Picco N, Morgan BP, Ghazal P. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opin Drug Discov 2021;16:537-51. [PMID: 33206027 DOI: 10.1080/17460441.2021.1851186] [Reference Citation Analysis]
74 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Markiewski MM, Daugherity E, Reese B, Karbowniczek M. The Role of Complement in Angiogenesis. Antibodies (Basel) 2020;9:E67. [PMID: 33271774 DOI: 10.3390/antib9040067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
76 Mao X, Zhou L, Tey SK, Ma APY, Yeung CLS, Ng TH, Wong SWK, Liu BHM, Fung YME, Patz EF Jr, Cao P, Gao Y, Yam JWP. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. J Extracell Vesicles 2020;10:e12031. [PMID: 33708358 DOI: 10.1002/jev2.12031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
77 Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 2020;11:1013. [PMID: 33243969 DOI: 10.1038/s41419-020-03221-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
78 Sebak AA, Gomaa IEO, ElMeshad AN, Farag MH, Breitinger U, Breitinger HG, AbdelKader MH. Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part I: In vitro Release and Intracellular Uptake Perspective. Int J Nanomedicine 2020;15:8845-62. [PMID: 33204091 DOI: 10.2147/IJN.S273713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
79 Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 2020;38:803-817.e4. [PMID: 33157048 DOI: 10.1016/j.ccell.2020.10.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 96] [Article Influence: 17.0] [Reference Citation Analysis]
80 Thurman JM, Laskowski J, Nemenoff RA. Complement and Cancer-A Dysfunctional Relationship? Antibodies (Basel) 2020;9:E61. [PMID: 33167384 DOI: 10.3390/antib9040061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
81 Elvington M, Liszewski MK, Atkinson JP. CD46 and Oncologic Interactions: Friendly Fire against Cancer. Antibodies (Basel) 2020;9:E59. [PMID: 33147799 DOI: 10.3390/antib9040059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Luo S, Wang M, Wang H, Hu D, Zipfel PF, Hu Y. How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application. Front Immunol 2020;11:593610. [PMID: 33193442 DOI: 10.3389/fimmu.2020.593610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sautès-Fridman C, Roumenina LT. B cells and complement at the forefront of chemotherapy. Nat Rev Clin Oncol 2020;17:393-4. [PMID: 32372036 DOI: 10.1038/s41571-020-0376-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
84 Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT. Complement System: Promoter or Suppressor of Cancer Progression? Antibodies (Basel) 2020;9:E57. [PMID: 33113844 DOI: 10.3390/antib9040057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
85 Nguyen HD, Allaire A, Diamandis P, Bisaillon M, Scott MS, Richer M. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets. BMC Med 2020;18:280. [PMID: 33059718 DOI: 10.1186/s12916-020-01748-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
86 Taylor RP, Lindorfer MA. How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2. Antibodies (Basel) 2020;9:E45. [PMID: 32899722 DOI: 10.3390/antib9030045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Zarantonello A, Presumey J, Simoni L, Yalcin E, Fox R, Hansen A, Olesen HG, Thiel S, Johnson MB, Stevens B, Laursen NS, Carroll MC, Andersen GR. An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase. J Immunol 2020;205:1678-94. [PMID: 32769120 DOI: 10.4049/jimmunol.2000528] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
88 Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer 2020;20:485-503. [PMID: 32694624 DOI: 10.1038/s41568-020-0281-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 196] [Article Influence: 41.5] [Reference Citation Analysis]
89 Jackson WD, Gulino A, Fossati-Jimack L, Castro Seoane R, Tian K, Best K, Köhl J, Belmonte B, Strid J, Botto M. C3 Drives Inflammatory Skin Carcinogenesis Independently of C5. J Invest Dermatol 2021;141:404-414.e6. [PMID: 32682912 DOI: 10.1016/j.jid.2020.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
90 Ding P, Li L, Li L, Lv X, Zhou D, Wang Q, Chen J, Yang C, Xu E, Dai W, Zhang X, Wang N, Wang Q, Zhang W, Zhang L, Zhou Y, Gu H, Lei Q, Zhou X, Hu W. C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation. Theranostics 2020;10:8619-32. [PMID: 32754267 DOI: 10.7150/thno.45058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
91 Lebegge E, Arnouk SM, Bardet PMR, Kiss M, Raes G, Van Ginderachter JA. Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy. Front Immunol 2020;11:1395. [PMID: 32733461 DOI: 10.3389/fimmu.2020.01395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
92 Gadwa J, Karam SD. Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer. Int J Radiat Oncol Biol Phys 2020;108:46-55. [PMID: 32629082 DOI: 10.1016/j.ijrobp.2020.06.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
93 Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020;5:113. [PMID: 32616710 DOI: 10.1038/s41392-020-00213-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 129] [Article Influence: 29.5] [Reference Citation Analysis]
94 Pedersen DV, Rösner T, Hansen AG, Andersen KR, Thiel S, Andersen GR, Valerius T, Laursen NS. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement. Mol Immunol 2020;124:200-10. [PMID: 32599335 DOI: 10.1016/j.molimm.2020.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Frid MG, Thurman JM, Hansen KC, Maron BA, Stenmark KR. Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement? Glob Cardiol Sci Pract 2020;2020:e202001. [PMID: 32478115 DOI: 10.21542/gcsp.2020.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
96 Sautès-fridman C, Verneau J, Sun C, Moreira M, Chen TW, Meylan M, Petitprez F, Fridman WH. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology 2020;48:101406. [DOI: 10.1016/j.smim.2020.101406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
97 Liu Z, Fu YX. Chemotherapy Induces Cancer-Fighting B Cells. Cell 2020;180:1037-9. [PMID: 32142652 DOI: 10.1016/j.cell.2020.02.046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
98 Trovato R, Canè S, Petrova V, Sartoris S, Ugel S, De Sanctis F. The Engagement Between MDSCs and Metastases: Partners in Crime. Front Oncol 2020;10:165. [PMID: 32133298 DOI: 10.3389/fonc.2020.00165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
99 Mastellos DC, Reis ES, Lambris JD. Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Front Immunol 2019;10:3029. [PMID: 31998311 DOI: 10.3389/fimmu.2019.03029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
100 Hata J, Machida T, Matsuoka K, Hoshi S, Akaihata H, Hiraki H, Suzuki T, Ogawa S, Kataoka M, Haga N, Ishibashi K, Homma Y, Sekine H, Kojima Y. Complement activation by autoantigen recognition in the growth process of benign prostatic hyperplasia. Sci Rep 2019;9:20357. [PMID: 31889151 DOI: 10.1038/s41598-019-57001-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
101 Gabriela-Freitas M, Pinheiro J, Raquel-Cunha A, Cardoso-Carneiro D, Martinho O. RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer. Biomolecules 2019;9:E769. [PMID: 31766768 DOI: 10.3390/biom9120769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
102 Fridman WH, Miller I, Sautès-Fridman C, Byrne AT. Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology 2020;158:303-21. [PMID: 31622621 DOI: 10.1053/j.gastro.2019.09.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]